Project description
Innovative technology for molecular optical imaging in deep tissue
Multispectral optoacoustic tomography (MSOT) is an innovative technology that enables molecular optical imaging in deep tissue. The technology is non-invasive and allows assessment of the concentration and distribution of molecules in the body, providing clinically important information on oxygenation, inflammation and tissue fibrosis. Despite its demonstrated scientific and clinical value, MSOT is not commercially available for the clinical market and is currently limited to research environments. The EU-funded FRONTIER project is supporting iThera Medical from Germany in optimising and translating the MSOT system from a research environment to a routine clinical imaging application.
Objective
Multispectral optoacoustic tomography (MSOT) is an innovative biomedical imaging technology that allows for molecular imaging in deep tissue. This noninvasive technology enables assessment of the concentration and distribution of a variety of clinically important molecules in the body and uniquely delivers information of e.g. oxygenation, inflammation, and fibrotic changes. MSOT has already demonstrated significant scientific and clinical value across a range of diseases and applications, making it a promising tool to diagnose diseases and monitor treatment response. Despite these early successes, the technology is not yet commercially viable on the broad clinical market and currently remains effectively confined to a research environment. FRONTIER will provide iThera Medical the means to translate an optimized MSOT system (MSOT Frontier) from a research environment to application in routine clinical imaging, thereby providing clinicians worldwide a powerful new diagnostic tool.
Fields of science
Keywords
Programme(s)
Funding Scheme
HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended FinanceCoordinator
81379 Munchen
Germany
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.